Press coverage about Sanofi (NYSE:SNY) has trended somewhat positive this week, Accern reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Sanofi earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.8122701533253 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:
- Sanofi’s (SNY) Neutral Rating Reiterated at Nord/LB (americanbankingnews.com)
- Analysts Expect Sanofi SA (SNY) Will Post Earnings of $0.84 Per Share (americanbankingnews.com)
- Future of Antifungal Drugs Market including key players Bayer Healthcare, Sanofi-Aventis, Novartis (journalhealthcare.com)
- Furosemide Market Business Overview, New Opportunities & SWOT Analysis: Sanofi Aventis, US Pharm Holdings, Mylan (journalhealthcare.com)
- Global Nano-drug Market 2018-2022: Roche, Sanofi, Merck, Pfizer, Abbott, EliLilly (anglophonetribune.com)
A number of equities research analysts have recently issued reports on the company. Zacks Investment Research cut Sanofi from a “hold” rating to a “sell” rating in a research note on Wednesday, February 14th. Sanford C. Bernstein reiterated a “market perform” rating and set a $45.00 price objective (down previously from $50.00) on shares of Sanofi in a research note on Thursday, February 8th. ValuEngine cut Sanofi from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Bank of America cut Sanofi from a “buy” rating to a “neutral” rating in a research note on Wednesday, December 6th. Finally, TheStreet cut Sanofi from a “b-” rating to a “c+” rating in a research note on Tuesday, February 13th. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating and three have issued a buy rating to the company’s stock. Sanofi has a consensus rating of “Hold” and a consensus target price of $49.33.
Sanofi (NYSE:SNY) last posted its quarterly earnings results on Wednesday, February 7th. The company reported $0.62 earnings per share for the quarter, missing analysts’ consensus estimates of $0.69 by ($0.07). Sanofi had a net margin of 23.25% and a return on equity of 24.30%. The business had revenue of $8.69 billion during the quarter, compared to the consensus estimate of $8.65 billion. During the same quarter last year, the company posted $1.25 EPS. The firm’s revenue was down 2.1% on a year-over-year basis. equities analysts forecast that Sanofi will post 3.36 earnings per share for the current year.
The firm also recently declared an annual dividend, which will be paid on Monday, June 4th. Investors of record on Thursday, May 10th will be paid a $1.8609 dividend. This represents a yield of 4.72%. The ex-dividend date of this dividend is Wednesday, May 9th. This is a boost from Sanofi’s previous annual dividend of $1.58. Sanofi’s dividend payout ratio is 35.14%.
WARNING: This piece was first reported by WKRB News and is owned by of WKRB News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.wkrb13.com/2018/04/02/sanofi-sny-getting-somewhat-positive-news-coverage-analysis-shows.html.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.